Journal: Current Therapeutic Research, Clinical and Experimental

Article Title: The Berberine Derivative BBR684 Inhibits VDAC Oligomerization to Suppress Ferroptosis in Acute Kidney Injury

doi: 10.1016/j.curtheres.2026.100825

Figure Lengend Snippet: BBR684 attenuates Erastin-induced ferroptosis in HK-2 cells by suppressing lipid peroxidation and activating the antioxidant response. (A) Flow cytometric analysis of lipid peroxidation using the C11-BODIPY probe in HK-2 cells treated as indicated for 12 hours. Data are presented as mean fluorescence intensity (MFI). (B) Intracellular Fe²⁺ levels measured by a ferrous iron colorimetric assay. (C, D) Levels of malondialdehyde (MDA, C) and reduced glutathione (GSH, D) in cell lysates. (E, F) Representative immunofluorescence images (E) and quantification (F) of 4-hydroxynonenal (4-HNE) adducts (red) in HK-2 cells. Nuclei were counterstained with DAPI (blue). Scale bar, 50 µm. (G) Western blot analysis of key ferroptosis-related proteins: glutathione peroxidase 4 (GPX4), heme oxygenase-1 (HO-1), and nuclear factor erythroid 2–related factor 2 (NRF2). β-actin served as the loading control. Data are from 3 independent biological replicates (n = 3) and presented as mean ± SEM. Significance was determined by one-way ANOVA followed by Tukey's HSD post hoc test. * P < 0.05, ** P < 0.01, *** P < 0.001; n.s., not significant.

Article Snippet: Antibodies against GPX4 (Catalog #3F5G5), HO-1 (Catalog #10701-1-AP), NRF2 (Catalog #16396-1-AP), VDAC (Catalog #10866-1-AP), Cleaved Caspase-3 (Catalog #68773-1-Ig), and CD45 (Catalog #98035-1-RR) were purchased from Proteintech.

Techniques: Fluorescence, Colorimetric Assay, Immunofluorescence, Western Blot, Control

Journal: iScience

Article Title: NUP62 promotes breast cancer progression and inhibits ferroptosis by stabilizing NRF2 in a KEAP1-dependent way

doi: 10.1016/j.isci.2026.115484

Figure Lengend Snippet: NUP62 stabilizes the NRF2 protein by decreasing its degradation (A) The expression levels of antioxidant and ferroptosis-related genes were quantified by RT-qPCR in indicated BC cells. (B) SLC7A11 and GPX4 protein expressions were measured by IF staining in BC cells with NUP62 overexpression. Scale bars, 10 μm. (C) SLC7A11 and GPX4 protein expressions were measured by IF staining in BC cells with NUP62 knockdown. Scale bars, 10 μm. (D) GPX4 enzyme activity was measured in BC cells after NUP62 knockdown or overexpression. (E) mRNA levels of NRF2 in the BC cells with NUP62 knockdown or overexpression. (F) Protein levels of NRF2, SLC7A11, and GPX4 in the BC cells with NUP62 knockdown or overexpression. (G) BC cells with NUP62 knockdown or controls were treated with MG132 (10 μM) for 4 h, and NRF2 protein levels were analyzed by western blotting. (H) NRF2 protein half-life of BC cells with NUP62 overexpression or knockdown was evaluated using western blotting. (I) NRF2 ubiquitination levels of BC cells with NUP62 overexpression or knockdown. (J) NUP62 knockdown inhibited NRF2 nuclear translocation in BC cells, as evidenced by IF microscopy and western blotting. Scale bars, 10 μm. (K) NUP62 overexpression facilitated NRF2 nuclear translocation in BC cells, as evidenced by IF microscopy and western blotting. Scale bars, 10 μm. Data are presented as the mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: GPX4 activity was quantified using a GPX4-specific Activity Assay Kit (Elabscience, E-BC-K883-M) following manufacturer's protocol.

Techniques: Expressing, Quantitative RT-PCR, Staining, Over Expression, Knockdown, Activity Assay, Western Blot, Ubiquitin Proteomics, Translocation Assay, Microscopy

Journal: iScience

Article Title: NUP62 promotes breast cancer progression and inhibits ferroptosis by stabilizing NRF2 in a KEAP1-dependent way

doi: 10.1016/j.isci.2026.115484

Figure Lengend Snippet: Eribulin destabilizes NRF2 protein and inhibits its nuclear localization (A) The protein levels of NRF2 in eribulin-treated BC cells with or without NUP62 knockdown. (B) NRF2 protein half-life of eribulin-treated BC cells with or without NUP62 knockdown, evaluated using western blotting. (C) NRF2 ubiquitination levels of eribulin-treated BC cells with or without NUP62 knockdown. (D) Nucleus-cytoplasm distribution of NUP62 in indicated BC cells, as evidenced by western blotting. (E) Nucleus-cytoplasm distribution of NUP62 in indicated BC cells, as evidenced by IF microscopy. (F) SLC7A11 protein expression , measured by IF staining in indicated BC cells. (G) GPX4 protein expression, measured by IF staining in indicated BC cells. Data are presented as the mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: GPX4 activity was quantified using a GPX4-specific Activity Assay Kit (Elabscience, E-BC-K883-M) following manufacturer's protocol.

Techniques: Knockdown, Western Blot, Ubiquitin Proteomics, Microscopy, Expressing, Staining

Journal: iScience

Article Title: NUP62 promotes breast cancer progression and inhibits ferroptosis by stabilizing NRF2 in a KEAP1-dependent way

doi: 10.1016/j.isci.2026.115484

Figure Lengend Snippet: Eribulin or NUP62 knockdown inhibits tumor growth in vivo (A) The volume and size of subcutaneous tumors in mice with or without eribulin treatment. (B) The volume and size of subcutaneous tumors in mice with NUP62 knockdown. (C) The volume and size of subcutaneous tumors in mice after NRF2 knockdown in NUP62-overexpressing MDA-MB-231 cells. (D–F) Representative IHC staining images of Ki-67, NUP62, NRF2, and GPX4 in tumor tissue sections of each group. (G–I) Lipid peroxidation and GSH/GSSG ratio were measured in tumor tissue of each group. (J) A schematic model showing that NUP62 protects BC cells against ferroptosis by sustaining NRF2 signaling activation. Data are presented as the mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: GPX4 activity was quantified using a GPX4-specific Activity Assay Kit (Elabscience, E-BC-K883-M) following manufacturer's protocol.

Techniques: Knockdown, In Vivo, Immunohistochemistry, Activation Assay